The problem of SARS-CoV-2 virus resistance to direct-acting antivirals
INTRODUCTION. The high prevalence of mutations in the SARS-CoV-2 genome raises particular concerns about the resistance of the virus to current antiviral therapy, including inhibitors of the main protease, or 3C-like protease (3CLpro), and RNA-dependent ...
E. L. Gasich +6 more
doaj +1 more source
Background and Aims Early stage administration of Paxlovid has been shown to improve the prognosis of mild to moderate COVID‐19 patients with high risk. However, few evidence was validated in severe COVID‐19 patients with hypoxemia.
Yu‐Ji Wang +8 more
doaj +1 more source
Paxlovid Awareness, Reporting Bias. [PDF]
Widera, Eric, Lee, Todd C, Prasad, Vinay
openaire +4 more sources
Québec authorizes pharmacists to prescribe Paxlovid
openaire +2 more sources
Carfilzomib Induced Microangiopathy due to Accumulation With Paxlovid
Philipponnet, Carole +4 more
openaire +2 more sources
Profound Synergistic Bradycardia: Pharmacokinetic Consequences of Paxlovid-Mediated CYP3A4 and CYP2D6 Inhibition on Ranolazine, Diltiazem, and Metoprolol. [PDF]
Bactawar SB, Gaibor C, Abdul-Waheed M.
europepmc +1 more source
Cardiovascular Risks of COVID-19 Therapeutics: Integrated Analysis of FAERS, Electronic Health Records, and Transcriptomics. [PDF]
Zhu X +8 more
europepmc +1 more source
Cardiovascular Outcomes in COVID-19 Patients Treated with Paxlovid: A Multicenter Retrospective Study. [PDF]
Chen WL +10 more
europepmc +1 more source
Safety and efficacy of major antiviral and immune therapies in pregnancy for maternal viral infections: evidence synthesis of maternal and neonatal outcomes. [PDF]
Sleman S +4 more
europepmc +1 more source
Acute pancreatitis temporally associated with COVID-19 pneumonia in a patient with post-tuberculosis chronic pulmonary aspergillosis: a case report. [PDF]
Yu W +6 more
europepmc +1 more source

